Vanda Pharmaceuticals announces FDA update for supplemental NDA for Hetlioz

Vanda Pharmaceuticals received a notification from the FDA stating that as part of its ongoing review of Vanda’s supplemental New Drug Application – sNDA – for Hetlioz in the treatment of insomnia characterized by difficulties with sleep initiation, the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time. No deficiencies were disclosed by the FDA in the notification, and the FDA stated that the notification does not reflect a final decision on the information under review. The FDA had assigned a Prescription Drug User Fee Act target date of March 4 for the completion of its review of the sNDA. Vanda believes that the timing of the FDA’s communication is part of an ongoing violation of the Federal Food Drug, and Cosmetic Act, or FDCA, which requires the FDA to either approve a new drug application or provide an opportunity for a hearing within 180 days after the filing of an application. Because Vanda submitted the sNDA on May 4, 2023, the FDA’s deadline under the FDCA was October 31. 2023. The FDA has not complied with the statute and has not timely approved the application or provided an opportunity for a hearing within the statutorily prescribed timeframe. Vanda is also challenging the FDA’s approvals of several generic versions of Hetlioz, which have been marketed since 2023.